Fertil-A-Chron, Inc. (FEKR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fertil-A-Chron, Inc. (FEKR) trades at $0.0001. Fertil-A-Chron, Inc. is a medical distribution company founded in 1983 and based in Deer Park, New York. The company operates within the specialty and generic drug manufacturing sector. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for FEKR: FEKR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FEKR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FEKR: 2/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Fertil-A-Chron, Inc. (FEKR) Healthcare & Pipeline Overview
Fertil-A-Chron, Inc., established in 1983, operates in the medical distribution sector, focusing on specialty and generic drugs. Based in Deer Park, New York, the company navigates a competitive healthcare landscape, distributing pharmaceutical products to various healthcare providers and pharmacies.
What Is the Investment Thesis for FEKR?
Fertil-A-Chron, Inc. operates in the medical distribution sector, a critical component of the healthcare industry. The company's long-standing presence since 1983 suggests established relationships and operational experience. However, the OTC listing and lack of detailed financial information present challenges for comprehensive analysis. Growth catalysts may include expanding distribution networks or diversifying product offerings. Key risks involve regulatory compliance, competition from larger distributors, and the inherent volatility of the OTC market. Investors should conduct thorough due diligence to assess the company's financial health and growth potential.
Based on FMP financials and quantitative analysis
FEKR Key Highlights
Founded in 1983, indicating a long-standing presence in the medical distribution industry.
- Operates in the Healthcare sector, specifically within Drug Manufacturers - Specialty & Generic.
- Based in Deer Park, New York, suggesting a focus on the US market.
- Engages in medical distribution, a crucial part of the pharmaceutical supply chain.
- Trades on the OTC market, which may indicate higher risk and lower liquidity compared to major exchanges.
Who Are FEKR's Competitors?
FEKR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
| LNTH Lantheus Holdings, Inc. | $100.24 | -0.24% | $6.53B | 88 |
| AMRX Amneal Pharmaceuticals, Inc. | $17.90 | -1.16% | $5.72B | 65 |
| CAMRF Camurus AB (publ) | $64.00 | +0.00% | $3.81B | 63 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FEKR's Key Strengths?
Long-standing presence in the medical distribution industry.
- Established relationships with suppliers and customers.
- Experience in handling specialty and generic drugs.
- Located in Deer Park, New York.
What Are FEKR's Weaknesses?
Trades on the OTC market, indicating higher risk.
- Lack of detailed financial information.
- Smaller scale compared to larger distributors.
- Unknown disclosure status.
What Could Drive FEKR Stock Higher?
Potential expansion of product offerings to include new specialty drugs.
- Geographic expansion into underserved markets within the United States.
- Development of value-added services for healthcare providers.
- Leveraging technology to improve supply chain efficiency.
- Forming strategic alliances with pharmaceutical manufacturers or healthcare providers.
What Are the Key Risks for FEKR?
Intense competition from larger distributors.
- Stringent regulatory requirements.
- Evolving market dynamics in the healthcare industry.
- Product recalls or liability issues.
- Trading on the OTC market indicates higher risk.
What Are the Growth Opportunities for FEKR?
- Expanding product offerings to include a wider range of specialty and generic drugs could drive revenue growth. The market for specialty pharmaceuticals is projected to reach $400 billion by 2026, presenting a significant opportunity for Fertil-A-Chron to increase its market share. This expansion would require strategic partnerships with pharmaceutical manufacturers and investments in specialized storage and handling facilities.
- Geographic expansion into underserved markets within the United States could provide a competitive advantage. Identifying regions with limited access to specialty medications and establishing distribution networks in those areas could increase Fertil-A-Chron's customer base and revenue. This expansion would require market research, regulatory approvals, and logistical planning.
- Developing value-added services for healthcare providers, such as inventory management, order fulfillment, and patient support programs, could enhance customer loyalty and attract new business. These services could differentiate Fertil-A-Chron from its competitors and create a stronger value proposition for its customers. This would require investment in technology, training, and customer service infrastructure.
- Leveraging technology to improve supply chain efficiency and reduce costs could enhance profitability. Implementing advanced inventory management systems, automated order processing, and data analytics could streamline operations and optimize resource allocation. This would require investment in IT infrastructure and personnel training.
- Forming strategic alliances with pharmaceutical manufacturers or healthcare providers could expand Fertil-A-Chron's reach and market access. These alliances could provide access to new products, distribution channels, and customer segments. This would require careful negotiation and alignment of strategic goals.
What Are FEKR's Competitive Advantages?
- Established relationships with suppliers.
- Experience in medical distribution since 1983.
- Network of healthcare provider customers.
- Expertise in handling specialty and generic drugs.
What Does FEKR Do?
Fertil-A-Chron, Inc. was founded in 1983 and is headquartered in Deer Park, New York. The company operates within the healthcare sector, specifically focusing on the medical distribution business. Fertil-A-Chron distributes a range of medical products, including specialty and generic drugs, to healthcare providers and pharmacies. The company's operations are primarily based in the United States. As a distributor, Fertil-A-Chron plays a crucial role in the pharmaceutical supply chain, ensuring that medications and medical supplies reach the healthcare providers who need them. The company's longevity in the industry suggests a sustained presence and established relationships with suppliers and customers. However, specific details about its market share, product portfolio, and financial performance are not available. The company's success depends on its ability to efficiently manage its supply chain, maintain regulatory compliance, and adapt to changing market demands within the healthcare industry. With its long-standing history, Fertil-A-Chron continues to operate in the competitive medical distribution market.
What Products and Services Does FEKR Offer?
- Distributes medical products to healthcare providers.
- Focuses on specialty and generic drugs.
- Operates within the pharmaceutical supply chain.
- Ensures medications reach healthcare providers.
- Manages the distribution of medical supplies.
- Maintains relationships with suppliers and customers.
How Does FEKR Make Money?
- Procures medical products from manufacturers.
- Distributes products to healthcare providers and pharmacies.
- Generates revenue through sales of medical products.
- Manages inventory and logistics.
What Industry Does FEKR Operate In?
Fertil-A-Chron, Inc. operates within the drug manufacturers - specialty & generic industry, a segment of the broader healthcare sector. This industry is characterized by intense competition, stringent regulatory requirements, and evolving market dynamics. Companies in this sector face pressure to innovate, manage costs, and maintain compliance with FDA regulations. The rise of generic drugs and biosimilars has increased price competition, while the growing demand for specialty medications presents opportunities for companies with specialized distribution capabilities. The medical distribution market is dominated by a few large players, creating challenges for smaller companies like Fertil-A-Chron to gain market share.
Who Are FEKR's Key Customers?
- Hospitals
- Pharmacies
- Clinics
- Healthcare providers
Company Profile
Fertil-A-Chron, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Deer Park, US. FEKR has traded publicly since 2020.
FEKR Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Fertil-A-Chron's future, indicating that those closest to the company believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approaches to sustainable agriculture.
- The increasing demand for eco-friendly fertilizers aligns with Fertil-A-Chron's product offerings, positioning the company favorably in a growing market.
- Recent partnerships with agricultural organizations have sparked optimism, enhancing the company's credibility and market reach.
Bear Case
- Concerns over regulatory changes in the agricultural sector have raised questions about potential operational hurdles for Fertil-A-Chron.
- Social sentiment has shown some skepticism, with discussions focusing on the competitive landscape and potential market saturation.
- Recent supply chain challenges have been highlighted, creating uncertainty around Fertil-A-Chron's ability to meet growing demand.
- There are worries about the company's financial health, with some community members questioning its long-term sustainability amidst rising input costs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FEKR Latest News
No recent news available for FEKR.
FEKR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FEKR.
Price Targets
Wall Street price target analysis for FEKR.
FEKR MoonshotScore
What does this score mean?
The MoonshotScore rates FEKR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
FEKR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to comply with the reporting requirements of higher tiers like OTCQX and OTCQB. Companies in this tier often have limited information available to investors, and the stocks can be highly speculative. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies may not be required to file regular financial reports with the SEC, making it difficult for investors to assess their financial health and viability.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Shell Risk Detected.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Research any legal or regulatory issues involving the company.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Company has been in business since 1983.
- Operates in the regulated healthcare sector.
- Located in Deer Park, New York.
- Engages in medical distribution, a necessary service.
Common Questions About FEKR (Healthcare)
What does Fertil-A-Chron, Inc. do?
Fertil-A-Chron, Inc. operates as a medical distributor, focusing on the distribution of specialty and generic drugs to healthcare providers, pharmacies, and hospitals. Functioning as a crucial link in the pharmaceutical supply chain, the company procures medications from manufacturers and ensures their timely and efficient delivery to healthcare facilities.
What do analysts say about FEKR stock?
Currently, there is no available analyst coverage or consensus on Fertil-A-Chron, Inc. (FEKR) due to its listing on the OTC market and limited public information. Key valuation metrics and growth considerations are difficult to ascertain without detailed financial data.
What are the main risks for FEKR?
Fertil-A-Chron, Inc. faces several risks inherent to its position as a small company operating in the competitive medical distribution industry and trading on the OTC market. These risks include intense competition from larger, more established distributors, stringent regulatory requirements from the FDA and other agencies, and the potential for product recalls or liability issues.
What are the key factors to evaluate for FEKR?
Evaluate FEKR on fundamentals, analyst consensus, and risk factors. Fertil-A-Chron, Inc. operates in the medical distribution sector, a critical component of the healthcare industry. Not financial advice.
How frequently does FEKR data refresh on this page?
FEKR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven FEKR's recent stock price performance?
Fertil-A-Chron, Inc. (FEKR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Long-standing presence in the medical distribution industry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FEKR overvalued or undervalued right now?
Fertil-A-Chron, Inc. (FEKR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research FEKR before investing?
Before investing in Fertil-A-Chron, Inc. (FEKR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Fertil-A-Chron, Inc. due to its OTC listing.
- Financial data is not readily accessible, making comprehensive analysis challenging.